These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22037511)

  • 61. Novel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients.
    Chen D; Fan J; Guo F; Qin S; Wang Z; Peng Z
    PLoS One; 2013; 8(8):e73405. PubMed ID: 23991193
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of pharmacogenetics to optimize immunosuppressive therapy.
    Macphee IA
    Ther Drug Monit; 2010 Jun; 32(3):261-4. PubMed ID: 20431509
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacogenetic biomarkers: cytochrome P450 3A5.
    MacPhee IA
    Clin Chim Acta; 2012 Sep; 413(17-18):1312-7. PubMed ID: 22037511
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
    Ware N; MacPhee IA
    Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
    Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
    Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
    Wang J
    Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
    Anglicheau D; Legendre C; Beaune P; Thervet E
    Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Choosing the right dose of tacrolimus.
    Lancia P; Jacqz-Aigrain E; Zhao W
    Arch Dis Child; 2015 Apr; 100(4):406-13. PubMed ID: 25416736
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
    Thervet E; Legendre C; Beaune P; Anglicheau D
    Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
    [TBL] [Abstract][Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.